Novartis prostate cancer therapy Pluvicto bags European Commission nod Ruchika Sharma14 Dec 2022 4:15 PM IST"The approval of Pluvicto by the European Commission marks a major milestone for patients with advanced prostate cancer who have few alternative...
JB Pharma slashes price of critical Heart Failure medicine AZMARDA (Sacubitril-Valsartan) by nearly 50 percent Ruchika Sharma5 Dec 2022 2:37 PM IST"This move by JB will not only help reduce the cost of treatment but will also help enhance the productive years of patients and their quality of...
Sandoz, Teva Pharma plans to ramp up biosimilars production Ruchika Sharma23 Nov 2022 1:30 PM ISTTeva Chief Executive KÃ¥re Schultz said the company was targeting "80% of what's going off-patent in the next 10 years" including big sellers like the...
Novartis considers selling ophthalmology, respiratory units to invest in cutting-edge medicines Ruchika Sharma17 Nov 2022 12:15 PM ISTAny sale of the ophthalmology and respiratory businesses is likely to begin in 2023, after the process for Sandoz is completed, the Bloomberg report...
BioNTech affiliate to acquire Novartis GMP-certified manufacturing facility in Singapore Ruchika Sharma15 Nov 2022 4:32 PM ISTSingapore: BioNTech SE has announced its Singapore affiliate BioNTech Pharmaceuticals Asia Pacific Pte. Ltd. had entered into an agreement...
Novartis allows generic Leukemia drug production in 7 nations: Bloomberg Ruchika Sharma21 Oct 2022 2:35 PM ISTChronic myeloid leukemia is a cancer that starts in the blood-forming cells found in bone marrow, before spilling into the general blood stream.
Novartis gets positive EMA panel opinion for prostate cancer drug Pluvicto Ruchika Sharma17 Oct 2022 11:32 AM ISTPluvicto is a radioligand therapy combining a targeting compound (ligand, in this case directed to PSMA) with a therapeutic radioisotope
US Supreme Court turns down Novartis bid to block launch of multiple sclerosis drug Gilenya generics Ruchika Sharma15 Oct 2022 1:30 PM ISTNovartis settled with some of the drugmakers it had sued, allowing for some Gilenya generics before a key patent's 2027 expiration.
California Court orders in favor of Plexxikon in dispute with Novartis Ruchika Sharma4 Oct 2022 6:00 PM ISTTokyo: Daiichi Sankyo has announced that the U.S. District Court for the Northern District of California has issued an order sustaining a jury...
Novartis to prioritise US market, unfazed by drug pricing pushback Ruchika Sharma25 Sept 2022 2:51 PM ISTNovartis aspire to "organically build its U.S. business to become a top-five player in the U.S. by 2027," it said in a statement.
Novartis to take US drug patent case to Supreme Court Ruchika Sharma22 Sept 2022 3:46 PM ISTZurich: Novartis AG plans to ask the U.S. Supreme court to uphold the validity of a patent it holds on the dosing regimen for multiple sclerosis drug...
Novartis under Swiss competition commission radar over unlawful use of patent Ruchika Sharma16 Sept 2022 7:30 PM ISTNovartis said COMCO had started an investigation in collaboration with the European Commission into the assertion of a patent in the broader field of...
